Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus

Brain Research

Volumn 814, Issue 1-2, 1998, Pages 179-185

  Mazarati, Andrey M ^a,b   Baldwin, Roger A ^b   Sankar, Raman ^a   Wasterlain, Claude G ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antiepileptic drugs; Diazepam; Phenytoin; Refractoriness; Self sustaining status epilepticus

Indexed keywords

ANTICONVULSIVE AGENT; DIAZEPAM; PHENYTOIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG EFFICACY; ELECTROGRAPHY; ELECTROSTIMULATION; EPILEPTIC STATE; NONHUMAN; PERFORANT NERVE TRACT; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; STIMULUS RESPONSE;

ANIMALS; ANTICONVULSANTS; DIAZEPAM; DRUG EVALUATION, PRECLINICAL; MALE; PHENYTOIN; RATS; RATS, WISTAR; STATUS EPILEPTICUS; TREATMENT OUTCOME;

EID: 0032517750     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)01080-4     Document Type: Article

References (31)

1. Borea P.A., Bonora D. Brain receptor binding and lipophilic character of benzodiazepines. Biochem. Pharmacol. 32:1983;603-607.
2. Commission on Classification and Terminology of the International League Against Epilepsy Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia. 22:1981;489-501.
3. DeLorenzo R.J., Hauser W.A., Towne A.R., Boggs J.G., Pellock J.M., Penberthy L., Garnett L., Fortner C.A., Ko D. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 46:1996;1029-1035.
4. DeLorenzo R.J., Pellock J.M., Towne A.R., Boggs J.C. Epidemiology of status epilepticus. J. Clin. Neurophysiol. 12:1995;316-325.
5. Drake C.T., Terman G.W., Simmons M.L., Milner T.A., D.D K., Schwartzkroin P.A., Chavkin C. Dynorphin opioids present in dentate granule cells may function as retrograde inhibitory neurotransmitters. J. Neurosci. 14:1994;3736-3750.
6. Jope R.S., Morrisett R.A., Snead O.C. Characterization of Lithium potentiation of pilocarpine-induced status epilepticus. Exp. Neurol. 91:1986;471-480.
7. Kangrga I., Randic M. Tachikinins and calcitonin-gene related peptide enhance release of glutamate and apartate from the rat spinal dorsal horn slices. J. Neurosci. 10:1990;1026-2038.
8. A receptor function in CA1 pyramidal neurons. Ann. Neurol. 38:1995;893-900.
9. A receptors. J. Neurosci. 17:1997;7532-7540.
10. Kuisma M., Roine R.O. Propofol in prehospital treatment of convulsive status epilepticus. Epilepsia. 36:1995;1241-1243.
11. Liu H., Mazarati A.M., Katsumori H., Wasterlain C.G. Limbic seizures mediated by phenotypic switch in hippocampal principal neurons. Soc. Neurosci Abstr. 24:1998;2140.
12. Lombroso C.T. Treatment of status epilepticus with diazepam. Neurology. 16:1966;629-634.
13. MacDonald R.L., Kelly K.M. Antiepileptic drug mechanisms of action. Epilepsia. 36:1995;S2-S12.
14. R.L. MacDonald, B.S. Meldrum, General principles: principles of antiepileptic drugs action, in: R.H. Levy, R.H. Mattson, B.S. Meldrum (Eds.), Antiepileptic Drugs, 4th edn., Raven Press, New York, 1995, pp. 61-77.
15. Mazarati A., Liu H., Wasterlain C., Langel U., Soomets U., Sankar R., Shin D. Galanin modulates status epilepticus. Soc. Neurosci. Abstr. 24:1998;1937.
16. Mazarati A., Wasterlain C. Loss of hippocampal inhibition and enhanced LTP after self-sustaining status epilepticus. Epilepsia. 38:1997;178. Suppl. 3.
17. Mazarati A., Wasterlain C. Pharmacological treatment of self-sustaining status epilepticus. Soc. Neurosci. Abstr. 23:1997;1687.
18. Mazarati A.M., Liu H., Wasterlain C.G. Opioid peptide pharmacology and immunochemistry in an animal model of self-sustaining status epilepticus. Neuroscience. 88:1999;. in press.
19. Mazarati A.M., Wasterlain C.G., Sankar R., Shin D. Self-sustaining status epilepticus after brief electrical stimulation of the perforant path. Brain Research. 801:1998;251-253.
20. Meldrum B.S. Update on the mechanism of action of antiepileptic drugs. Epilepsia. 37:1996;S4-S11. Suppl. 6.
21. Morrisett R.A., Jope R.S., Snead O.C. Effects of drugs on the initiation and maintenance of status epilepticus induced by administration of pilocarpine to lithium-pretreated rats. Exp. Neurol. 97:1987;193-200.
22. Racine R.J. Modification of seizure activity by electrical stimulation. Electroencephalogr. Clin. Neurophysiol. 32:1972;281-294.
23. Rice A.C., DeLorenzo R.J. The effect of NMDA receptor inhibition during status epilepticus on refractoriness to treatment. Soc. Neurosci. Abstr. 23:1997;812.
24. A receptors. Science. 269:1995;977-981.
25. Stecker M.M., Kramer T.H., Raps E.C., O'Meeghan R., Dulaney E., Skaar D.J. Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. Epilepsia. 39:1998;18-26.
26. N.Y. Walton, D.M. Treiman, Rational polytherapy in the treatment of status epilepticus, in: I.E. Leppik (Ed.), Rational Polypharmacy, 1996, pp. 123-139.
27. C.G. Wasterlain, J.M. Bronstein, A.M. Morin, B.E. Dwyer, R. Sankar, Translocation and autophosphorylation of brain calmodulin kinase II in status epilepticus, Epilepsy Res., Suppl. 9, Molecular Neurobiology of Epilepsy (1992) 231-238.
28. Working Group on Status and Epilepticus Treatment of convulsive status epilepticus. JAMA. 270:1993;854-859.
29. Yaffe K., Lowenstein D.H. Prognostic factors for pentobarbital therapy for refractory generalized status epilepticus. Neurology. 43:1993;895-900.
30. Zini S., Roisin M.P., Armengaud C., Ben-Ari Y. Effects of potassium channels modulators on the release of glutamate induced by ischaemic-like conditions in rat hippocampal slices. Neurosci. Lett. 153:1993;202-205.
31. Zini S., Roisin M., Langel U., Bartfai T., Ben-Ari Y. Galanin reduces release of endogenous excitatory amino acids in the rat hippocampus. Eur. J. Pharmacol. 245:1993;1-7.